Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apraclonidine Ophthalmic Solution in Adult Subjects With Ocular Redness
NCT07531043Phase 3Recruiting
- Sponsor
- Alcon Inc.
- Start
- Sep 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Ocular hyperemia comparing Apraclonidine Ophthalmic Solution with Vehicle (2 arms). Primary endpoints: Change from baseline in investigator-assessed ocular redness at 15 minutes post-instillation and Change from baseline in investigator-assessed ocular redness at 840 minutes (14 hours) post-instillation. Started Sep 2026; status: recruiting.
02
Drugs
apraclonidine
03
Conditions
Ocular hyperemia
Beyond the preview
Go deeper on NCT07531043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07531043.